RVS News
Most Popular RVS Story
Crucell decides to tackle universal RSV vaccine project
When Johnson & Johnson handed over €302 million for an 18 percent stake in Crucell last year, the two companies signed off on an ambitious new vaccines venture, with the Dutch biotech Read more...
Latest Headlines
- Crucell decides to tackle universal RSV vaccine projectJune 24, 2010
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
More Research Reports >>
